May 6, 2014 9:10 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a report published Tuesday, Deutsche Bank analyst Alethia Young initiated coverage on
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
(NASDAQ: VSTM) with a Buy rating and $14.00 price target.In the report, Deutsche Bank noted, “Verastem's lead asset is VS-6063 for the treatment of mesothelioma currently in pivotal studies. We see VSTM as a platform cancer company based on its robust scientific grounding around cancer stem cells. Pipeline opportunities are a free call option, in our view, while mesothelioma market size & potential clinical success are unappreciated. VSTM's market cap is ~$200M and shares are trading near cash of ~$4.5/sh. Shares are also trading at 52-week low although clinical progress has been made in 12 months.”Verastem closed on Monday at $8.05.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.